Ranked by evidence rather than hype, the "top" weight loss peptides are the approved incretin medicines — tirzepatide, semaglutide, and liraglutide — followed by the clinical-stage candidate retatrutide. Research compounds like AOD-9604 and 5-amino-1MQ appear on many lists but have little or no published human efficacy data.
An evidence-weighted view of 'top' peptides
If "top" means the strongest published human evidence for weight loss, the ranking is not controversial — it comes straight from randomized trial results:
- Tirzepatide (Zepbound, Mounjaro) — a GLP-1/GIP dual agonist. In SURMOUNT-1 (n=2,539 adults with obesity), 72 weeks of weekly tirzepatide produced mean weight loss of 15.0% (5 mg), 19.5% (10 mg), and 20.9% (15 mg) versus 3.1% for placebo (NEJM 2022) — the largest effect of any approved medicine in this class.
- Semaglutide (Wegovy, Ozempic) — a GLP-1 receptor agonist. In STEP 1 (n=1,961), 68 weeks of weekly 2.4 mg semaglutide produced a mean 14.9% weight loss versus 2.4% for placebo (NEJM 2021). It also has the deepest overall evidence base, including cardiovascular outcome data.
- Liraglutide (Saxenda) — an older, once-daily GLP-1 agonist. In the SCALE trial (n=3,731), 3.0 mg daily produced a mean 8.4 kg loss versus 2.8 kg for placebo over 56 weeks (NEJM 2015) — clearly effective, but roughly half the effect of the newer weekly drugs.
These three are approved medicines with FDA labels, defined dosing, and characterized side-effect profiles. A head-to-head look at the first two is on the semaglutide vs tirzepatide page.
The clinical-stage tier: retatrutide
One rung down sits retatrutide, a GLP-1/GIP/glucagon triple agonist. Its phase 2 trial (n=338) reported the largest mean weight reduction yet seen in an obesity trial — 24.2% at the 12 mg dose versus 2.1% for placebo at 48 weeks (NEJM 2023). Impressive as that is, phase 2 results from a few hundred participants are not the same as approval: phase 3 trials exist precisely because efficacy and safety estimates often shift in larger populations. Retatrutide belongs on a watch list, not on the same shelf as approved medicines.
This tier is also the fastest-moving part of the field. Any evidence-ranked list written today will need revising as phase 3 programs report — which is itself a useful test of a source's honesty: lists that never change, and never distinguish approved from investigational compounds, are tracking inventory rather than evidence.
Experimental peptides that appear on 'top' lists
Most "top peptides for weight loss" lists found online also include research compounds. Their actual evidence:
- AOD-9604 — an hGH fragment developed for obesity in the early 2000s; phase 2 trials were underway by 2002 (Curr Opin Investig Drugs 2004), but the program never produced published human efficacy results or an approval. Its supporting data are mouse studies from two decades ago.
- HGH fragment 176-191 — the parent fragment AOD-9604 was derived from; same story, with even less independent literature.
- 5-Amino-1MQ — a small molecule (not a peptide) that reduced weight and fat mass in diet-induced obese mice (Biochem Pharmacol 2018); no published human trials.
The gap between tiers is not subtle: it is the difference between "20% mean weight loss in 2,539 people over 72 weeks" and "weight loss in mice, human data absent."
Reading rankings against evidence and risk
Rankings that put research compounds beside approved medicines usually reflect what a vendor sells, not what the literature shows. Two things are worth keeping separate when reading any such list:
- Effect size only counts when measured in humans. Rodent lipolysis does not rank against STEP 1 or SURMOUNT-1; it belongs in a different table entirely.
- "Top" for efficacy is not "top" for everyone. The approved drugs carry known trade-offs — predominantly gastrointestinal side effects and a labeled thyroid C-cell tumor warning — which trial populations and product labels document, and which clinicians weigh against individual health history.
This site's safest peptide for weight loss page covers the risk side of the same ranking, and do peptides really work for weight loss? covers the evidence landscape more broadly.